Rotator cuff disease is one of the most common injuries in the world, with more than 3 million in the U.S. alone suffering damage to the tissues connecting muscle to bone in the shoulder.
But the standard treatment for rotator cuff disease is clunky, painful and often inefficient, with an estimated 40% of patients experiencing re-tearing of the rotator cuff following surgery.
For Rotation Medical, a Minnesota-based medical device company, that clinical gap presents a major window of opportunity.
Rotation’s treatment, a biologic implant derived from the achilles tendon of cows, is designed to spur new growth to thicken and strengthen the damaged tendon. Last year, the company raised more than $27 million in a Series B round to support a commercial launch and post-market clinical studies.
Rotation Medical CEO Martha Shadan recently sat down with MassDevice.com publisher Brian Johnson in another episode of DeviceTalks, to discuss the company’s treatment and how the orthopedic industry is changing forever:
